Dual targeting of BCL2 and CDK4/6 has shown good activity in ER + breast cancer [73], and so choriocarcinoma patients with intrinsically lower tumour expression for BCL2 may be particularly responsive to treatment with Palbociclib. This evidence concerns the gene BCL2 and breast carcinoma.